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Abstract
mPEG and mPEG-peptide based drug delivery systems were prepared by conjugating doxorubicin (DOX) to these carrier
molecules via hydrazone bond. The peptide, AT1, with a sequence of CG3H6G3E served as mPEG and doxorubicin attachment
site. Histidines were incorporated to the sequence to improve pH responsiveness of the carrier molecule. Hydrodynamic diam-
eters (mean sizes) of mPEG-based drug delivery system (mPEG-HYD-DOX) were measured as 9 ± 0.5 and 7 ± 0.5 nm at pH 7.4
and pH 5.0, respectively. Mean size of the aggregates of the peptide containing drug delivery system, mPEG-AT1-DOX, was
determined as 12 ± 2 nm at neutral pH. At pH 5.0, on the other hand, mPEG-AT1-DOX exhibited a size distribution between 20
and 100 nm centered at about 40 nm. Comparison of % DOX release values of the drug delivery systems obtained at pH 7.4 and
pH 5.0 indicated that mPEG-AT1-DOX has enhanced pH sensitivity. DOX equivalent absolute IC50 values were obtained as
0.96 ± 0.51, 21.9 ± 5.9, and 5.55 ± 0.75 μg/mL for free DOX, mPEG-HYD-DOX, and mPEG-AT1-DOX, respectively.
Considering more pronounced pH sensitivity and cytotoxicity of mPEG-AT1-DOX, the use of both pH responsive functional
groups and acid cleavable chemical bond between the carrier molecule and drug can be a promising approach in the design of
drug delivery systems for cancer therapy.
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Introduction
pH responsive drug delivery systems (DDS) have been re-
ceived increasing interest in recent years. Especially in cancer
treatment, pH programmed fast release of antitumor drug has
been proposed to increase therapeutic activity of the drug and
to overcome the multidrug resistance (MDR) problem of can-
cer cells [1–7]. Correlation between fast release of the drug
and its cytotoxic effect was demonstrated by comparing the %
viability of MDA-MB-231 human breast adenocarcinoma
cells exposed to free paclitaxel and paclitaxel loaded nanopar-
ticles of poly(ethylene oxide) (PEO)-modified poly(β-amino
ester) (PbAE) and PEO-modified poly(ε-caprolactone) (PCL).
It was shown that at high paclitaxel concentrations, pH re-
sponsive PEO-PbAE based paclitaxel carrier system exhibited
superior antitumor activity than free paclitaxel and PEO-PCL-
paclitaxel system [8]. Additionally, in vitro and in vivo eval-
uations revealed that pH sensitive micelles decorated with
folate molecules suppressed both sensitive and MDR tumors
of MCF-7 remarkably [1].
It was reported that cytoplasmic pH around 7.2, drops to ~6
in endosomes, and reaches to ~5 in lysosomes of drug sensi-
tive tumor cells [4, 9]. pH responsive antitumor drug delivery
systems exploit the pH gradient in the endocytic pathway to
facilitate fast accumulation of the drugs by dissolution or col-
lapse of the nanoparticles in acidic environment of these or-
ganelles [2]. pH responsiveness can be imparted to the drug
delivery system by incorporating pH sensitive functional
groups into the carrier molecules or by attaching antitumor
drug to the delivery system via an acid labile chemical bond.
For the former case, pH sensitive functional group can be
ionizable or acid degradable and drug can be attached to the
carrier system via intermolecular attraction forces. Histidine
[1, 10–12], N,N-dialkylaminoethyl methacrylates (DEA) [2],
β-amino esters [8, 13], and 2-((((5-methyl-2-(2,4,6-
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trimethoxyphenyl)-1,3-dioxan-5-yl)methoxy)carbonyl) ami-
no) ethyl methacrylate (TTAMA) [14] are a few examples of
the monomers used to synthesize carrier molecules where pH
responsiveness is achieved by protonation/deprotonation of ion-
izable building blocks. Acid degradable ketals [15, 16], acetals
[17, 18], and hydrazone [19] functional groups in the backbone
of the polymers or copolymers cause disintegration of the poly-
mer and, hence, accelerate release of the drug at acidic condi-
tions. Acid cleavable hydrazone [20–24], acetal [25], and cis-
aconityl [26] bonds have also been used for covalent conjugation
of antitumor drugs to the drug delivery systems.
Even designed to be pH responsive, one of the possible
concerns of the drug delivery systems where drug molecules
are hold via intermolecular interactions is considerable release
of the cargo at physiological pH. Drug release at neutral pH
can be minimized by chemically attaching the drug to the
carrier molecule. However, most of these systems exhibited
much slower release at acidic conditions as well compared to
their counterparts.
In this study, it was aimed to evaluate the performance of
a pH responsive drug delivery system containing both pH
responsive functional groups and acid cleavable chemical
bond between drug and carrier molecule. For this reason,
mPEG and mPEG-peptide based drug delivery systems
were obtained by covalently attaching DOX to the carrier
molecules using acid cleavable hydrazone bond. In these
DDSs, PEG was used as a hydrophilic block to increase
solubility and blood circulation time of the DDSs during
the transport. The designed peptide containing histidines
were used to impart additional pH responsiveness to the
carrier molecule. Peptide-free drug delivery system,
mPEG-HYD-DOX, was synthesized as a control drug de-
livery system. Purity of the carrier molecules were assessed.
Size distribution, stability, drug release and cytotoxic prop-
erties of the DOX-conjugated molecules were investigated.
Materials and methods
Materials
Methoxypolyethylene glycol-propionic acid (mPEG-
COOH; MW = 5000 g/mol, ≥ 80% COOH functionality),
methoxypolyethylene glycol maleimide (mPEG-MAL;
MW = 5000 g/mol, ≥ 90% maleimide functionality), adipic
acid dihydrazide (AADH), dimethyl sulfoxide (DMSO),
and diethyl ether (DEE) were purchased from Sigma-
Aldrich. (3-Dimethylaminopropyl)-N′-ethylcarbodiimide
hydrochloride (EDC.HCl) and N-hydroxysuccinimide
(NHS) were obtained from P3 Biosystems and Alfa Aesar,
respectively. Synthesis grade trifluoroacetic acid (TFA;
Merck) and doxorubicin hydrochlor ide (Medkoo
Biosciences) were used for the drug conjugation reactions.
For the peptide synthesis, Rink amide MBHA resin, Fmoc-
His-Trt-OH, Fmoc-Gly-OH, Fmoc-Cys-Trt-OH, Fmoc-
Glu-(OtBu)-OH (NovaBiochem), N,N,N′,N′-tetramethyl-
O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate
(HBTU), hydroxybenzotriazole (HOBt) purchased from P3
Biosystems, dimethyl formamide (DMF), 4-methylmorpholine
(NMM), dichloromethane (DCM) obtained from Sigma-
Aldrich, and piperidine (Acros) were used. Triisopropyl silane
(TIS; Sigma-Aldrich) and 1,3-dimethoxybenzene (DMB;
Sigma-Aldrich) were employed in the cleavage reactions.
Sodium phosphate monobasic, sodium chloride, sodium hy-
droxide (Sigma-Aldrich), imidazole (Fluka), anhydrous 4-
morpholineethanesulfonic acid (MES; AppliChem), acetic acid
and hydrochloric acid (Merck) were used in the preparation of
buffers. HisPur Ni-NTA (Thermo Fisher Scientific) and
Sephadex LH-20 (GE Healthcare) resins were employed in the
affinity and gel permeation chromatography (GPC), respectively.
SnakeSkin dialysis tubing (MW 3.5 kDa) purchased from
Thermo Fisher Scientific was utilized in dialysis and drug release
experiments.
Sinapic acid, FTIR grade potassium bromide (Sigma-
Aldrich) and deuterium oxide (D2O; Merck) were used in
MALDI-TOF, FTIR and NMR spectroscopy sample prepara-
tions, respectively.
Gentamycin sulfate, European grade fetal bovine serum
(FBS), trypsin-EDTA solution C and 0.5% trypan blue solution
were purchased from Biological Industries. RPMI-1640 with L-
glutamine and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) were obtained from Sigma-Aldrich and
Amresco, respectively. All the chemicals and solvents were used
without purification.
Synthesis of methoxypoly(ethylene glycol)
-hydrazone-doxorubicin (mPEG- HYD-DOX) conjugate
Model anticancer drug, doxorubicin, was conjugated to the
carrier molecule by following two steps:
& conversion of carboxylic acid groups of mPEG into hy-
drazide groups
& attachment of doxorubicin to hydrazide functionalized
mPEG via hydrazone bond.
Hydrazide form of mPEG denoted as mPEG-HYD was pre-
pared using EDC coupling reaction with AADH in the presence
of NHS as given in Fig. 1. In a typical reaction, 3 mmol AADH
was dissolved in 10 mL PBS buffer (100 mM sodium phosphate
containing 150 mM NaCl) at pH 7.4 by sonicating at 40-45 °C
(Solution 1). In a separate vial, 50 mg (~0.01 mmol) mPEG-
propionic acid, 1 mmol EDC.HCl, and 0.4 mmol NHS were
dissolved in 6 mL 25 mM MES buffer containing 150 mM
NaCl at pH 6.0 (Solution 2). Next, the solution 2 was stirred at
room temperature for 15 min, and it was added onto the solution
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1 dropwise. After that, pH of the combined solution was adjusted
to 7.4 and the reaction was allowed to proceed overnight at
30 °C. To isolate mPEG compounds, the reaction mixture was
dialyzed against 100 mM phosphate buffer containing 150 mM
NaCl at neutral conditions followed by against deionized water
to remove excess buffer components in addition to remaining
small molecular weight excess reactants and by-products.
Afterwards, the solution was freeze dried and the product obtain-
ed was stored at -20 °C. Yield of the final product (mixture of
mPEG-propionic acid and mPEG-hydrazide) was obtained as 75
± 5%. Hydrazide functionalization was determined as 54 ± 1%
using 1H NMR. No further purification was applied prior to
DOX conjugation.
Ketone group of DOX was conjugated to the hydrazide of
mPEG-HYD via the formation of acid cleavable hydrazone
bond to obtain the final drug delivery system. DOX conjuga-
tion reaction given in Fig. 1 was performed in DMSO (1 mL
DMSO: 5 mg mPEG-hydrazide) using TFA (% 2 by volume)
as a catalyst at 30 °C for 3 days by protecting the reaction
mixture from light. In these reactions, DOX:mPEG-HYD ra-
tio was used as ~ 6.8:1 in terms of molar basis. After the
reaction was completed, the reaction mixture was precipitated
over cold DEE and centrifuged to obtain mainly mPEG-DOX
conjugates. The supernatant corresponds to some portion of
free DOX as depicted from orange color. Residual DEE in the
conjugates was removed by drying in a fume hood for a few
hours and the dried conjugates were resuspended in DMSO.
Gel permeation chromatography was applied to remove re-
maining free DOX in the conjugates using Sephadex LH-20
resin in DMSO. Then, isolated conjugates (eluted first with
red color) were precipitated onto cold DEE to get rid of
DMSO. After drying of the conjugates in a fume hood, they
were dissolved in deionized water, freeze dried and stored at
20 °C (Yield = 65 ± 3%).
Synthesis of methoxypolyethylene
glycol–peptide-hydrazone–doxorubicin
(mPEG-AT1-DOX) conjugate
mPEG-peptide-DOX conjugate system was prepared using
four steps:
& Peptide synthesis
& Conjugation of mPEG and peptide
& Synthesis of hydrazide form of the mPEG-peptide
& Attachment of the drug
The peptide, denoted as AT1 with a sequence of CG3H6G3E
was synthesized by employing Fmoc strategy on a Rink amide
MBHA resin (0.66 mmol/g functionality) at 0.1 mmol scale
using 0.4 mmol amino acid/3 mL of DMF. Solid phase peptide
synthesis (SPPS) was carried out on an automated peptide syn-
thesis instrument (AAPTEC Focus XI). Deprotection reactions
were performed using 20% piperidine in DMF for 15 min and
were repeated three times. Coupling reactions were carried out
using 0.395 mmol HBTU and 2.5 mL of 0.4 M NMM as
activating agents for 1 h. In addition to these agents, 0.44 mmol
HOBt was also used during the coupling of histidine and cys-
teine residues to prevent racemization. For each amino acid,
double coupling cycles were performed. At the end of the syn-
thesis, the resin was washed with DCM and dried under N2
f low a t room tempera tu re . C leavage reac t ions
Fig. 1 Reaction scheme of
mPEG-HYD-DOX
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were conducted using 92.5:5:2.5 TFA:DMB:TIS cocktail
(20 mL cocktail/g resin) for 2.5 h [27]. The resin was filtered
using a polypropylene column and the supernatant was precip-
itated over cold DEE with 1:10 cleavage cocktail: DEE volume
ratio. The precipitate was washed with DEE and centrifuged.
After evaporation of DEE under N2 flow at room temperature,
the raw peptide was dissolved in 1 mL 1% acetic acid in deion-
ized water, freeze dried and stored at -20 °C.
PEGylation of the raw peptide was carried out using
Michael addition reaction involved in the mPEG-MAL and
thiol group of cysteine at the N-terminus of the peptide (Fig.
S1). Approximately, 20 mg peptide (0.014 mmol) was dis-
solved in 10 mL PBS buffer under N2 gas flow for 10 min
to prevent air oxidation of cysteines. 75 mg mPEG-MAL
(0.015 mmol) was added under N2 blanketing and the reaction
was allowed to proceed for 4 h. Unreacted mPEG-MAL was
separated using affinity chromatography with Ni-NTA resin
which selectively binds to histidines of the peptide and
mPEG-peptide conjugate. For the affinity chromatography,
50 mM sodium phosphate containing 0.3 M NaCl at pH 8.0
was used as binding and washing buffer. Unbound mPEG-
MAL was washed away until no PEG was detected in the
solution according to the results of a colorimetric assay based
on the complex formation of barium iodide and PEG [28]. The
peptide and mPEG-peptide were eluted from the resin using
50 mM phosphate buffer containing 0.3 M NaCl and 0.5 M
imidazole at pH 7.4. To isolate mPEG-peptide conjugate, the
peptide was removed by dialysis against deionized water
using SnakeSkin dialysis tubing membrane with MWCO
3.5 kDa. Finally, the solution was freeze-dried, and mPEG-
AT1 conjugate was stored at -20 °C. Hydrazide form of
mPEG-AT1 was obtained using the reaction between AADH
and carboxylic acid group of glutamic acid residue at the C-
terminus of the peptide. Same experimental procedures used
to prepare mPEG-HYD-DOX were applied to obtain the final
conjugate system, mPEG-AT1-DOX as given in Fig. S2
(Yield = 43 ± 3%).
Characterization of the carrier molecules
Hydrazide conjugation reaction with AADHwas monitored by
NMR spectroscopy. Approximately, 2.5 mg sample was dis-
solved in 0.6 mL D2O and
1H NMR spectrum was taken using
Varian Vnmr 400 model spectrometer. NMR data were ana-
lyzed using ACDLAB 12, 1D NMR Processor software.
FTIR experiments were conducted using KBr pellet technique.
Prior to analyses, moisture of the samples was removed/
reduced by keeping in a vacuum oven at room temperature
for overnight. Approximately, 1 mg sample was dispersed in
150mg potassium bromide to prepare a pellet. The spectra were
taken between 400 and 4000 cm−1 by using Shimadzu
IRPrestige-21 FTIR-8400S model spectrophotometer.
Purity of the peptide and mPEG-AT1 conjugate was
assessed using reverse phase HPLC method with Agilent
1100 model HPLC system. 0.1% TFA in deionized water
and 0.08% TFA in acetonitrile were used as Solvent A and
Solvent B, respectively. 100 μL filtered sample prepared in
0.1% TFA in water (~1–2 mg/mL) was injected to C18 ana-
lytical column (Inertsil WP-300, 5μm, 4.6 × 100 mm).
Solvent A:B ratio was changed from 95:5 to 30:70 within
65 min and the sample eluted from the column was monitored
using a UV detector at 214 nm. Analyses were carried out at
1 mL/min solvent flow rate.
Molar mass of the peptide was determined using
electrospray ionization mass spectroscopy (ESI-MS). The ex-
periments were performed with an LTQ XL linear ion-trap
mass spectrometer (Thermo Finnigan) equipped with an
electrospray ionization source. The peptide sample was dis-
solved in 1% acetic acid in ultra-pure water and mixed with
equal proportion of HPLC-grade methanol and infused direct-
ly into the mass spectrometer. Matrix-assisted laser
desorption/ionization time of flight mass spectrometer
(Bruker Daltonics-Autoflex III Smartbeam MALDI TOF/
TOF MS) was used for identification of the mPEG-peptide
conjugate. The sample was dissolved in 0.1% TFA in ultra-
pure water and sinapic acid was used as a matrix.
Characterization of the DOX conjugated drug delivery
systems
DOX conjugation percentages of the drug delivery systems
(mPEG-HYD-DOX, and mPEG-AT1-DOX) were determined
using Perkin Elmer Lambda-45 model UV-Vis spectroscopy.
Approximately, 0.5 mg conjugate was dissolved in 700 μL
deionized water. The exact concentration was recorded for
the calculations. Absorbance value of the solution was deter-
mined at 488 nm and % DOX functionalization values of the
samples were calculated based on the extinction coefficient of
free DOX, 11500 L·mol−1·cm−1 [29].
Size distributions of the samples were obtained using
Malvern ZetaSizer Nano ZS model instrument via dynamic
light scattering technique. Diffusion coefficients of the sam-
ples were determined by applying CONTIN method and con-
verted to hydrodynamic diameters via Stoke-Einstein equa-
tion provided by the software of the instrument. 3 mg/mL
sample was dissolved in deionized water and diluted two-
fold using 20 mM phosphate buffer containing 300 mM
NaCl at pH 7.4 or 20 mM acetate buffer containing 300 mM
NaCl at pH 5.0 and filtered. Measurements were performed
after equilibrating the cuvette for at least 5 min at 25 °C and
repeated three times. Size distributions of the samples were
determined within a few hours after preparation of the solu-
tions and after incubating the solutions for one day at 37 °C.
Atomic force microscopy (AFM) observations were car-
ried out on a Digital Instruments-MMSPM Nanoscope lV
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type of instrument. The sample, mPEG-AT1-DOX, was dis-
solved in deionized water and filtered. 2 μL of the solution
was pipetted onto a freshly cleaved mica plate and diluted
using 8 μL filtered deionized water. The plate was protected
from light and air-dried. The image was taken in tappingmode
using a silicon probe with a spring constant of 0.4 N/m and
resonance frequency of 70 kHz (Bruker, Scanasyst-Air mod-
el). Height of the sample was determined using NanoScope
Analysis software. Lateral dimensions and shape of the sam-
ple were analyzed using ImageJ software [30].
Drug release profiles of mPEG-HYD-DOX and mPEG-
AT1-DOX were obtained using dialysis procedure. 1.5 mg
sample dissolved in 1 mL buffer (10 mM acetate buffer con-
taining 150 mM NaCl at pH 5.0 or 10 mM phosphate buffer
containing 150 mM NaCl at pH 7.4) was placed in a dialysis
membrane with a MWCO of 3.5 kDa. The membrane was
transferred to a 50 mL Falcon tube containing 25 mL buffer
solution and the lid of the tube was wrapped with parafilm to
prevent evaporation. The tube was incubated at 37 °C by
shaking at 150 rpm. 200 μL of solution was withdrawn and
replaced with the same volume of fresh buffer at certain time
intervals (1, 3, 6, 10, 24, 48, 56, and 72 h). Released DOX
amount was determined using fluorescence emission intensity
data at 590 nm. Emission spectra were recorded between 400
and 700 nm with excitation wavelength of 480 nm, excitation
slit width of 5 nm, emission slit width of 20 nm and scan rate
of 125 nm/min. The experiments were performed on a Perkin
Elmer LS55 model fluorescence spectrophotometer.
Cytotoxicity tests were carried out using MTT assay on
human lung adenocarcinoma epithelial cell line (A549 cells).
For a typical MTT assay, 90 μL aliquots of the cells (5 × 103
cells/well) were seeded in a 96 well microplate (number of
replicates = 4). Then, the cells were incubated at 37 °C in 5%
CO2 atmosphere for 24 h. At the end of the incubation period,
10 μL sample in sterile PBS buffer was added over the cells.
The cells were incubated for another 24 h at the same condi-
tions. The medium was discarded and changed with the fresh
medium, then, incubated for another 24 h prior to application
of MTT assay [20]. Next, 10 μL MTT (5 mg/mL in sterile
PBS buffer) was added to the wells and the microplates were
further incubated for 3 h. After centrifuging at 1800 rpm and at
room temperature for 5 min, the medium was carefully re-
moved by a pipette and the microplate was inverted and blot-
ted with a napkin. Next, 100 μL DMSO was added and the
microplates were shaken at 150 rpm for 5 min. Absorbance
values were recorded at 570 nm with a reference wavelength
of 690 nm using VarioSkan FlashMultimode Reader (Thermo
Scientific). Absolute IC50 values of the samples were estimat-
ed as the concentration that corresponds to 50% cell viability
using cubic spline interpolation method. Finally, independent
2-sample t-tests of the data were conducted using Minitab
software. p-value less than 0.05 was considered to be statisti-
cally significant.
Results and discussion
Synthesis of mPEG based carrier molecule
In the first step of the preparation of the DOX-conjugated DDSs,
hydrazide functionalized carrier molecules, mPEG and mPEG-
AT1 were synthesized using EDC and NHS activated carboxylic
acid-hydrazide coupling reaction. Hydrazide functionalization of
mPEG-COOH was monitored using FTIR spectroscopy, quali-
tatively. FTIR spectra of mPEG-COOH and mPEG-HYD are
given in Fig. 2. In the FTIR spectrum of mPEG-COOH charac-
teristic C-O stretching band of ether backbone was observed at
1110 cm−1. The bands around 1465 and 2885 cm−1 are due to the
respective bending and stretching of C-H groups. Aweak band
observed at 1727 cm−1 corresponds to carbonyl group. In the
hydrazide functionalized sample, on the other hand, this band
became undetectable. In addition to C-O and C-H group vibra-
tion bands observed mainly for mPEG-COOH, N-H bending
band around 1655–1665 cm−1 appeared in the FTIR spectrum
of mPEG-HYD suggesting the hydrazide functionalization reac-
tion was successful.
To get quantitative information for hydrazide conjugation,
1H NMR spectroscopy was used. 1H NMR spectra of mPEG-
COOH, AADH andmPEG-HYD samples in D2O are given in
Fig. S3, Fig. S4 and Fig. 3, respectively. NMR spectrum of
mPEG-COOH indicated a singlet at 3.31 ppm and a large peak
at 3.64 ppm attributed to 3 protons of CH3-O (methoxy)
groups and ether backbone protons (O-CH2-CH2)n, respec-
tively. By comparing the area of these protons number average
molecular weight (Mn) of mPEG-COOH was obtained as
~5400 Da (spec value = 5000 Da). Additionally, the chemical
shift at 2.62 ppm is due to 2 protons next to carboxylic acid
group and using the area of this peak, percentage of COOH
functional group was calculated as 88% (spect value ≥80%).
Similar to the quantitative analysis of mPEG-COOH, num-
ber average molecular weight of mPEG-HYDwas estimated as
5500 Da close to that of the mPEG-COOH. This indicates that
Mn of the polymer did not change significantly during the hy-
drazide functionalization reaction and purification steps. Using
Fig. 2 FTIR spectra of (a) mPEG-COOH and (b) mPEG-HYD
J Polym Res (2018) 25: 104 Page 5 of 12 104
the area of the chemical shift at 1.56 ppm that corresponds to 4
protons, hydrazide conjugation percentage was estimated as
54%. Comparing the COOH functionality of mPEG-
propionic acid (88%), it is apparent that not all COOH groups
were replaced with hydrazide group.
Hydrazone bond is, perhaps, the mostly employed acid
cleavable bond in the preparation of pH responsive drug de-
livery systems. In these systems, hydrazone bond forms as a
result of the reaction between ketone group of a drug, mostly
doxorubicin, and hydrazide group of any carrier molecule.
Hydrazide groups have been introduced to drug delivery sys-
tems via different routes. For example, Etrych et al. (2001)
obtained hydrazide functionalized N-(2-hydroxypropyl)
methacrylamide (HPMA)-methacryloylglycyl-glycine 4-
nitrophenyl ester (Ma-Gly-Gly-ONp) random copolymers
using the reaction between 4-nitrophenoxy (ONp) group and
hydrazine monohydrate in methanol [31]. In another study,
hydrazide groups were conjugated to aspartic acid side chains
of mPEG-polyaspartate block copolymers in tert-
butyloxycarbonyl (BOC) protected form via acid anhydride
reaction in the presence of N-methylmorpholine (NMM),
isobutyl chloroformate (IBCF), carbazic acid tert-butyl ester
(Cat-BE) and dimethyl acetamide (DMAc). BOC group was,
then, removed using TFA to obtain hydrazide functionalized
form of the block copolymer [20]. Hydrazide form of a PEG
copolymer containing allyl groups was prepared using two
consecutive reactions including the reaction with methyl
mercaptoacetate in the presence of AIBN in THF followed
by the reaction with hydrazine hydrate in THF [32].
Hermanson (1996), on the other hand, proposed a simple
route performed in aqueous medium using EDC as a zero
length crosslinker to couple carboxyl groups and primary
amine group of a dihydrazide molecule forming an amine
reactive o-acylisourea as an intermediate product [33]. It was
reported that in the presence of water, yield of amide forma-
tion can be quite low because of fast hydrolysis rate of o-
acylisourea. Introduction of NHS, stabilizes this intermediate
molecule and forms amine reactive NHS ester, which is more
stable towards hydrolysis [34]. Thus, in this study, EDC and
NHS ester were used to prepare hydrazide form of the carrier
mPEG or mPEG-AT1 molecule. Hydrazide functionalization
percentage of mPEG-HYD (54%) was obtained to be lower
than those obtained in organic solvents (> 75%) [20, 31, 32].
Nevertheless, this value was enough to attach DOXmolecules
and to test the performance of the DOX-conjugated drug de-
livery systems.
Synthesis of mPEG-peptide based carrier molecule
The de novo peptide, AT1, was designed to exploit both
ionization properties and reactive functional groups of ami-
no acid side chains. The peptide sequence contains C, G, H,
and E residuals with the following assignments. At the N-
terminus of the peptide, cysteine (C) with thiol functional
group served as mPEG conjugation site. Histidines (H) were
incorporated to provide pH responsiveness to the peptide as
its pKa value is around 6.0. At the C-terminus, glutamic acid
(E) having COO− group was used to attach DOX. Glycine
Fig. 3 1H NMR spectrum of mPEG-HYD in D2O
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(G) which is the smallest amino acid with a hydrogen atom
in its side chain, was placed nearby C and E to minimize
steric effects during the conjugation reactions.
Purity of AT1 peptide was assessed by ESI-MS and HPLC
data given in Fig. S5 and Fig. 4, respectively. In the mass
spectrum, theoretical molar mass of the peptide (1414 Da)
was confirmed by the peaks corresponding to single and mul-
tiple charged peptide m/z values. HPLC elution curve of the
peptide presented a large peak around 24.9 min with relatively
small peaks just next to this major peak (Fig. 4a). The pres-
ence of this highly pure fraction in the chromatogram along
with the consistency of theoretical and experimental molar
mass value of the peptide obtained from mass spectrum clear-
ly indicated the peptide was synthesized at high purity.
Purity of the isolated mPEG-AT1 conjugate was evaluated
by HPLC and MALDI-TOF mass spectroscopy. HPLC curves
given in Fig. 4 indicated that AT1 peptide, mPEG-AT1 and
mPEG-maleimide eluted in 24.9, 32.0 and 36.3 min, respec-
tively, in the order of increasing hydrophobicity. In the chro-
matogram of mPEG-AT1, no significant fractions correspond-
ing to peptide or parent PEG molecule were observed suggest-
ing mPEG-AT1 conjugate have high purity (Fig. 4c). MALDI-
TOF analysis was conducted to determine molar mass of the
conjugate. In themass spectrum of the conjugate a peakwas ob-
served at ~6600 Da (Fig. S6), which is close to its theoretical
molar mass confirming that the conjugation reaction was
successful.
Further evidence of the PEGylation of the peptide was
also provided by comparing the fingerprints of the peptide,
mPEG-MAL, and the conjugate in their FTIR spectra as
given in Fig. 5. It is quite clear that the conjugate have a
FTIR pattern matching to both parent molecules. More spe-
cifically, the band around 2900 cm−1 assigned to C-H
stretching of PEG backbone appears in the FTIR spectra
of both the PEG and the conjugate. Similarly, amide I and
amide II bands of the peptide in 1500–1700 cm−1 region
were also observed in the spectrum of the conjugate. Thus,
these three characterization methods confirmed that high
purity of mPEG-peptide conjugate was isolated.
Characterization of the DOX conjugated drug delivery
systems
% of DOX conjugation values of mPEG-HYD-DOX and
mPEG-AT1-DOX were obtained as 62 ± 7% and 35 ± 3%,
respectively. For mPEG-HYD-DOX, DOX conjugation per-
centage obtained seemed slightly higher than hydrazide
functionalization (~54%). This can be attributed remaining free
DOX in the conjugates that could not be separated during GPC.
In the purification of the conjugates, a clear color difference was
apparent in the elution fractions of GPC (conjugates = red, free
DOX= orange) suggesting most of the free DOX was separat-
ed. Nevertheless, standard deviation values of % DOX
conjugations indicate the difference between hydrazide conju-
gation % and DOX conjugation % are within experimental
error. DOX conjugation % of the mPEG-peptide based DDS
was obtained to be lower than that of the mPEG based DDS.
The possible reason can be increased steric hindrance effect of
the more crowded environment nearby the drug conjugation
site in the case of the mPEG-peptide DDS.
Dynamic light scattering was used to determine aggrega-
tion state and stability of the DOX-conjugated DDSs. Figure 6
shows size (hydrodynamic diameter) distributions of mPEG-
COOH and mPEG-HYD in PBS buffer (pH 7.4) and mPEG-
AT1 in both PBS buffer at pH 7.4 and acetate buffer at pH 5.0.
Average size of the samples was determined to be similar for
all of the samples with a value around 4 ± 0.5 nm. It was also
observed that pH change did not affect the size of mPEG-AT1.
It is possible to predict hydrodynamic diameter (DH) of
PEG in Å as a function of its molar mass (Mn) in Da via the
following correlation [35]:
DH ¼ 0:3824 Mn0:559
The equation above gave size of a PEG molecule with a
molar mass of 5000 Da as ~4.4 nm, which is consistent with
the experimental values. Thus, it can be concluded that neither
functionalized mPEG molecules nor mPEG-AT1 conjugate
has aggregation tendency.
Fig. 5 FTIR spectra of (a) AT1, (b) mPEG-MAL, and (c) mPEG-AT1
Fig. 4 HPLC curves of (a) AT1, (b) mPEG-MAL, and (c) mPEG-AT1
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Size distributions of the DOX-conjugated DDSs followed
completely different patterns. Results of the measurements tak-
en within a few hours after the dissolution of the conjugates in
appropriate buffer and after incubating the solution at 37 °C for
1 day are given in Figs. 7 and 8, respectively. Average sizes of
mPEG-HYD-DOX at pH 7.4 and pH 5.0 upon immediate mea-
surement were obtained as about 9 ± 0.5 nm and 7 ± 0.5 nm,
respectively. Aggregated structures of mPEG-HYD-DOXwere
observed to be stable with at most a few nm reduction in the
average size after 24 h incubation period independent of pH.
Average size of the conjugate at pH 7.4 is about twice of that of
mPEG-HYD molecule. Thus, it can be suggested that the drug
conjugation to the carrier molecule, mPEG-HYD, triggered
self-assembly of the DOX-conjugated DDS resulting micellar
aggregates, in which drug molecules are in the core and hydro-
philic PEG molecules are at the surface. Conjugation of DOX
to PEG-peptide conjugates containing enzymatically degrad-
able units has also been resulted in the formation of aggregated
structures with aggregation number dictated by architecture and
molecular weight of PEG molecules [36]. The two pKa values
of doxorubicin have been reported as 8.2 and 9.5 [37]. Below
pH 8.2, aglycone part is neutral whereas amine group of the
daunosamine is protonated [37, 38]. However, various experi-
mental techniques including NMR, absorption, florescence,
and mass spectroscopy, viscosity, and permeation measure-
ments confirmed that charge repulsions can be eliminated by
the addition of salt and suppressed by attraction forces causing
self-association (dimerization below 5 mM concentration) of
doxorubicin [37–41]. Viscosity measurements also showed no
change in aggregation state between pH 7.5 and 5 [40]. Hence,
aggregate structure of the drug delivery systems was stabilized
mainly by π-π stacking and hydrophobic interactions between
doxorubicin molecules, as expected [39, 42].
mPEG-peptide based DDS, mPEG-AT1-DOX, have simi-
lar type of chemical bond between the carrier and drug mole-
cule as in mPEG-HYD. However, different from this mPEG
(only)-based DDS, mPEG-AT1-DOX also contains pH re-
sponsive peptide domain. Therefore, the role of the peptide
domain in the DOX-conjugated DDS can be elucidated by
comparing its size distribution data with those of mPEG-
HYD-DOX. At pH 7.4, slightly larger average size (~12 ±
2 nm) was obtained for mPEG-AT1-DOX. Considering the
size of the aggregates is slightly higher than twice of the size
of the parent molecule, mPEG-AT1, it can deduced that like-
wise mPEG-HYD-DOX, mPEG-AT1-DOX also formed ag-
gregated structures. At pH 5, on the other hand, larger aggre-
gate sizes ranging from 20 to 100 nm centered around 40 nm
were obtained for mPEG-AT1-DOX. Similarly, mean size of
PEG-poly(histidine) and PEG-poly(L-lactide) mixed micelles
measured as 129 ± 10 nm at pH 7.4 was reported to gradually
increase as pH decreased (232 ± 25 nm at pH 6.5) [43]. Thus,
it is likely that the repulsions between positively charged his-
tidines at pH 5.0 prevented close packing of the molecules and
drove the molecules to form loosely packed and more hydrat-
ed structures with higher mean hydrodynamic diameter. No
significant change in the stability of mPEG-AT1-DOX aggre-
gates was observed at neutral pH. However, approximately
10 nm nanometer increase in its mean size upon was obtained
upon incubation of mPEG-AT1-DOX in pH 5.0 buffer at
37 °C for 24 h.
Fig. 8 Size distributions of the DOX-conjugated DDSs obtained after
24 h incubation at 37 °C
Fig. 7 Size distributions of the as prepared DOX-conjugated DDSs
Fig. 6 Size distributions of mPEG molecules with different functional
groups and mPEG-AT1 conjugate
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Morphology of mPEG-AT1-DOX structures was ob-
served using AFM. 2D and 3D AFM images of the sample
are given in Fig. 9. Elongated structures with an average
aspect ratio of 2.0 ± 0.4 were obtained. Heights of the struc-
tures were measured as between 2.3 and 3.7 nm with an
average value of ~2.9 nm. This value corresponds to the
diameter of the collapsed aggregate in dried state where
PEG chains are no longer extended and hydrated state and
hence the height measured mostly describes the size of the
hydrophobic core of the aggregate [44]. Feret diameter and
minimum caliper diameter of the core of the aggregates
were measured as 18.8 ± 4.8 nm and 9.2 ± 2.7 nm, higher
than expected, due to tip broadening effect which limits the
resolution of lateral dimensions of the structures in AFM.
DOX release profiles of mPEG-HYD-DOX and mPEG-
AT1-DOX at pH 7.4 and pH 5.0 are given in Fig. 10. At the
end of 72 h, % DOX release values of mPEG-HYD-DOX
were obtained as 8 ± 1% and 12 ± 2% at pH 7.4 and at
pH 5.0, respectively. These results indicated that mPEG-
HYD-DOX have slight pH responsive drug release behavior.
mPEG-AT1-DOX presented faster DOX release at pH 5 (30 ±
7%) compared to pH 7.4 (14.5 ± 2.5%) and, hence, more
pronounced pH programmed release behavior compared to
the mPEG-only DDS. It is likely that addition of histidines
into the drug delivery system increased DOX release at acidic
pH due to decreased attractions between aggregated structures
of mPEG-AT1-DOX thereby facilitating contact of the solvent
molecules with the acid cleavable hydrazone bonds.
Comparison of the other DDS systems suggested that the re-
lease behavior of mPEG-HYD is similar to mPEG-PLLA-
HYD-DOX system where single DOX was attached to the
carrier amphiphilic molecule which has inherent tendency to
form compact aggregates with a size of 89 ± 12 nm. For
mPEG-PLLA-HYD-DOX, % DOX release values were re-
ported as 20 and 24% at the end of 25 h at pH 5.0 and
pH 7.4, respectively [45]. pH responsiveness was observed
to be more apparent for multivalent mPEG-polyaspartate-
HYD-DOX drug delivery system having mean aggregate size
of 65 nm as revealed by no release at all at neutral pH. At
pH 5.0, on the other hand, % DOX release was obtained as
28% at the end of 72 h [20]. PEO-g-HYD-DOX system with
a size of 9–11 nm exhibited much higher DOX release rate
(90% at pH 5.0 at the end of 72 h) than that of the drug delivery
systems that are forming larger aggregates [32]. Considering
the correlation between aggregation behavior of drug delivery
systems and their drug release abilities, mPEG-AT1-DOX
would be expected to release higher amount of DOX at acidic
pH. As revealed by the size of the mPEG-AT1-DOX, the num-
ber of charged histidines in the peptide seemed not enough to
completely destabilize the aggregates. Thus, it can
Fig. 9 a 2D and (b) 3D AFM images of mPEG-AT1-DOX
Fig. 10 DOX release curves of mPEG-HYD-DOX and mPEG-AT1-
DOX at pH 7.4 and pH 5.0
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be speculated that incorporation of more histidines to the pep-
tide block of the carrier molecule can be resulted in higher pH
sensitivity and, hence, faster DOX release.
Cytotoxicity results of mPEG-COOH, AADH, mPEG-
HYD and AT1 peptide are given in Fig. S7. No significant
cytotoxicity of these samples was revealed. Growth inhibition
curves of free DOX and the DOX-conjugated DDSs are given
in Fig. 11. The resultant DOX equivalent IC50 values were
obtained as 0.96 ± 0.51, 21.9 ± 5.9, and 5.55 ± 0.75 μg/mL for
free DOX, mPEG-HYD-DOX, and mPEG-AT1-DOX, respec-
tively. Statistical analysis revealed that all p-values for the IC50
values of free DOX, mPEG-HYD-DOX, and mPEG-AT1-
DOX pairs were obtained to be less than 0.05 indicating statis-
tically significant differences between the cytotoxicity of the
samples (Table S1). DOX-conjugated DDSs exhibited higher
IC50 value than free DOX. It was reported that biodegradable
block copolymer doxorubicin conjugates and a peptide-
doxorubicin conjugate where DOX was attached to the carrier
molecule via an acid cleavable bond exhibited cytotoxicity low-
er than that of free DOX for A549 cell-line as free DOX mol-
ecules are more readily internalized and transported to nucleus
with a faster rate [46, 47]. Of the DOX-conjugated systems
developed in current study, mPEG-AT1-DOX presented higher
toxicity. Histidine-rich peptides and polypeptides have been
shown to act as endosomal escape facilitator due to proton
sponge effect [48, 49]. Considering no significant toxicity of
AT1, the superior cytotoxicity of mPEG-AT1-DOX can be at-
tributed to its more pronounced pH responsive property and
possible endosome disruption ability.
Conclusions
pH sensitive DOX-conjugated drug delivery systems based
on mPEG (mPEG-HYD-DOX) and mPEG-peptide (mPEG-
AT1-DOX) were synthesized. DOX was attached to both
DDSs via acid cleavable hydrazone bond. The peptide,
AT1, was designed to have a hexa-histidine domain to im-
part additional pH sensitivity to the DDS. Both DDSs
formed aggregated structures upon DOX conjugation.
Compared to mPEG-HYD-DOX, mPEG-AT1-DOX exhib-
ited more pronounced pH responsiveness as indicated by its
% DOX release performance at pH 5.0 and pH 7.4. IC50
values were obtained in increasing order of free DOX <
mPEG-AT1-DOX <mPEG-HYD-DOX.
Superior drug release properties and cytotoxicity of
mPEG-AT1-DOX compared to those of mPEG-HYD-
DOX conjugate system suggested the conjugates containing
both pH sensitive domains and chemical bonds could be
promising drug delivery systems. However, to exploit en-
hanced permeability and retention (EPR) effect, larger size
of the DOX-conjugated carrier molecule should be re-
quired. Such a system may be possible by the development
of a multivalent system where a number of drug molecules
can be attached or by decreasing the length of the hydro-
philic PEG block. Additionally, pH sensitivity of the DDS
can be improved by the incorporation of more histidines to
the peptide domain.
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